About coagulation factor viia
Recombinant activated coagulation factor
Used for
- Treats bleeding episodes in hemophilia A or B with inhibitors
- Treats bleeding in acquired hemophilia
- Treats bleeding in congenital factor VII deficiency
- Helps control bleeding in Glanzmann thrombasthenia when platelet transfusions fail
Usual adult dose
Varies by condition: commonly 90 micrograms/kg intravenously every 2–3 hours initially for hemophilia with inhibitors; specialist-directed.
Usual dose in children
Condition-specific specialist dosing; commonly 90 micrograms/kg intravenously every 2–3 hours initially for hemophilia with inhibitors.
Common side effects
- Fever
- Headache
- Nausea or vomiting
- Blood clots, including serious arterial or venous events
Important warnings
- Can cause life-threatening blood clots; risk may be higher with other clotting medicines.
- Use only under specialist supervision, with monitoring of bleeding and clotting complications.
- Tell clinicians about heart or blood-vessel disease and all medicines, especially other clotting agents.
Pregnancy
Human pregnancy data are limited; use only when clearly needed and benefits outweigh potential risks.
Breastfeeding
It is unknown whether this medicine passes into breast milk; weigh treatment benefits against breastfeeding considerations.
Interactions
- Activated prothrombin complex concentrate may increase clot risk; avoid combined use when possible.
- Antifibrinolytics such as tranexamic acid may increase clot risk when used together.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.